| pubmed-article:7723928 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7723928 | lifeskim:mentions | umls-concept:C0002395 | lld:lifeskim |
| pubmed-article:7723928 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7723928 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:7723928 | lifeskim:mentions | umls-concept:C0524474 | lld:lifeskim |
| pubmed-article:7723928 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7723928 | pubmed:dateCreated | 1995-5-24 | lld:pubmed |
| pubmed-article:7723928 | pubmed:abstractText | In a double-blind, placebo study, acetyl-L-carnitine was administered to 7 probable Alzheimer's disease patients who were then compared by clinical and 31P magnetic resonance spectroscopic measures to 5 placebo-treated probable AD patients and 21 age-matched healthy controls over the course of 1 year. Compared to AD patients on placebo, acetyl-L-carnitine-treated patients showed significantly less deterioration in their Mini-Mental Status and Alzheimer's Disease Assessment Scale test scores. Furthermore, the decrease in phosphomonoester levels observed in both the acetyl-L-carnitine and placebo AD groups at entry was normalized in the acetyl-L-carnitine-treated but not in the placebo-treated patients. Similar normalization of high-energy phosphate levels was observed in the acetyl-L-carnitine-treated but not in the placebo-treated patients. This is the first direct in vivo demonstration of a beneficial effect of a drug on both clinical and CNS neurochemical parameters in AD. | lld:pubmed |
| pubmed-article:7723928 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7723928 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7723928 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7723928 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7723928 | pubmed:issn | 0197-4580 | lld:pubmed |
| pubmed-article:7723928 | pubmed:author | pubmed-author:KanferJ NJN | lld:pubmed |
| pubmed-article:7723928 | pubmed:author | pubmed-author:PettegrewJ... | lld:pubmed |
| pubmed-article:7723928 | pubmed:author | pubmed-author:KlunkW EWE | lld:pubmed |
| pubmed-article:7723928 | pubmed:author | pubmed-author:McClureR JRJ | lld:pubmed |
| pubmed-article:7723928 | pubmed:author | pubmed-author:PanchalingamK... | lld:pubmed |
| pubmed-article:7723928 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7723928 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:7723928 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7723928 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7723928 | pubmed:pagination | 1-4 | lld:pubmed |
| pubmed-article:7723928 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:meshHeading | pubmed-meshheading:7723928-... | lld:pubmed |
| pubmed-article:7723928 | pubmed:articleTitle | Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. | lld:pubmed |
| pubmed-article:7723928 | pubmed:affiliation | Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, PA 15213, USA. | lld:pubmed |
| pubmed-article:7723928 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7723928 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7723928 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7723928 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7723928 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7723928 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7723928 | lld:pubmed |
